Tagraxofusp
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tagraxofusp: From Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) to Esotropia
One-Sentence Summary
Tagraxofusp is a CD123-targeted diphtheria toxin fusion protein; trial descriptions in this Evidence Pack reference it as approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN), though no EU marketing or formal original-indication data is included in this pack. The TxGNN model’s top-ranked prediction is Esotropia, but this pairing is supported by zero clinical trials and zero publications, and the Evidence Pack’s own mechanistic review flags it as likely embedding noise rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — referenced in trial evidence; not confirmed via EU authorization data, as the drug is not currently marketed in the EU |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank (data gap DG002). Based on information available in the clinical trial evidence within this pack, tagraxofusp (also known as SL-401) is a recombinant fusion protein combining human interleukin-3 with a truncated diphtheria toxin, engineered to kill CD123-expressing malignant cells; it is referenced as approved for treatment of BPDCN.
Esotropia is a form of strabismus caused by extraocular muscle or neuromuscular dysfunction. There is no established biological relationship between CD123 expression, diphtheria-toxin-mediated cytotoxicity, and ocular muscle alignment disorders.
The Evidence Pack’s own mechanistic assessment for this specific pairing states explicitly that there is no known mechanistic link, and that the high TxGNN score most likely reflects noise in the knowledge-graph embedding rather than a biologically plausible signal. No clinical trials or publications were identified to support this indication, and the recommendation is accordingly Hold.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Tagraxofusp does not currently hold any EU marketing authorization (0 licenses on record); market status is recorded as Not marketed.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CD123-directed diphtheria toxin fusion protein / immunotoxin) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or literature evidence supports a mechanistic or clinical link between tagraxofusp and esotropia. The Evidence Pack’s own mechanistic review classifies this pairing as likely knowledge-graph noise (Evidence Level L5, Decision Stage S0), and no further development action is warranted for this specific disease pairing.
To proceed, the following is needed:
- TFDA/SmPC label data (warnings, contraindications) — currently a blocking data gap (DG001)
- DrugBank mechanism-of-action confirmation (DG002)
- If repurposing screening continues for this drug, prioritize the rank-2 candidate “pre-malignant neoplasm” instead — it has Evidence Level L3 with 5 registered trials in CD123-positive myeloid malignancy/myelofibrosis, offering a materially stronger (though still imperfect) mechanistic and clinical rationale than the top-ranked esotropia prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.